A network meta-analysis comparing alemtuzumab to natalizumab in patients with relapsing-remitting multiple sclerosis with rapidly evolving severe disease

被引：0
|
作者：
Guo, J. D. [1 ]
Das Gupta, R. J. [1 ]
Fahrbach, K. [2 ]
Wissinger, E. [2 ]
Cox, F. M. [1 ]
机构：
[1] Sanofi Genzyme, Cambridge, MA USA
[2] Evidera, Bethesda, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1479
引用
收藏
页码：772 / 772
页数：1
相关论文
共 50 条
  • [21] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [22] Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis
    Wiendl, H.
    Arnold, D. L.
    Hupperts, R. M.
    Giovannoni, G.
    Margolin, D. H.
    Kasten, L.
    Havrdova, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 256 - 256
  • [23] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [24] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [25] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
  • [26] Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis
    Prakash, R. S.
    Snook, E. M.
    Lewis, J. M.
    Motl, R. W.
    Kramer, A. F.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (09) : 1250 - 1261
  • [27] Meta-analysis of randomized controlled trials and real-world evidence comparing natalizumab and fingolimod for relapsing-remitting multiple sclerosis
    Efthimiou, O.
    Acosta, C.
    Saunders-Hastings, P.
    Pellegrini, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 170 - 171
  • [28] A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK
    Montgomery, Stephen M.
    Maruszczak, Maciej J.
    Slater, David
    Kusel, Jeanette
    Nicholas, Richard
    Adlard, Nicholas
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 474 - 482
  • [29] COMPARING THE EFFICACY OF FIRST AND SECOND GENERATION DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
    Fogarty, E.
    Schmitz, S.
    Walsh, C.
    Barry, M.
    VALUE IN HEALTH, 2013, 16 (07) : A618 - A618
  • [30] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
12345